Sepsis is one of the 10 leading causes of death worldwide. According to the Centers for Disease Control, more than 1.5 million people in the United States contract sepsis yearly, and around 250,000 of these people die from its associated complications. In 2015, sepsis...
Noble Life Sciences Now Offers Live Animal Imaging for Preclinical Stu PerkinElmer IVIS Lumina LT III Gain simultaneous insights into the efficacy, kinetics, target, and mechanism of action of your drug candidate non-invasively. The IVIS is particularly suited for...
Introduction The immune system is extraordinarily effective at eliminating small, local infections. However, when infection occurs systemically, such as in bacterial septicemia, a cascade of events is initiated in which potent mediators released by the immune system...
Noble Life Sciences, in collaboration with ImQuest Biosciences, has optimized the peritonitis/sepsis mouse model to screen for new antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). The model’s popularity derives from its ease of use with small and expensive animals, short-duration experiments with reproducible infections, and simple end-points.
Sykesville, MD, and Fairfax, VA, December 21, 2020 – Noble Life Sciences (NLS), a preclinical contract research organization located in Sykesville, MD, has signed a Collaboration Agreement with George Mason University (Mason) to access the National Center for...